25.53
price down icon1.31%   -0.34
pre-market  Vorhandelsmarkt:  25.49   -0.04   -0.16%
loading
Schlusskurs vom Vortag:
$25.87
Offen:
$25.83
24-Stunden-Volumen:
35.74M
Relative Volume:
0.87
Marktkapitalisierung:
$144.68B
Einnahmen:
$63.63B
Nettoeinkommen (Verlust:
$8.03B
KGV:
18.11
EPS:
1.41
Netto-Cashflow:
$8.23B
1W Leistung:
-1.31%
1M Leistung:
-4.45%
6M Leistung:
-10.58%
1J Leistung:
-7.37%
1-Tages-Spanne:
Value
$25.46
$25.91
1-Wochen-Bereich:
Value
$25.46
$26.69
52-Wochen-Spanne:
Value
$24.48
$31.54

Pfizer Inc Stock (PFE) Company Profile

Name
Firmenname
Pfizer Inc
Name
Telefon
(212) 733-2323
Name
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Name
Mitarbeiter
88,000
Name
Twitter
@Pfizer
Name
Nächster Verdiensttermin
2025-02-04
Name
Neueste SEC-Einreichungen
Name
PFE's Discussions on Twitter

Vergleichen Sie PFE mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - General icon
PFE
Pfizer Inc
25.53 144.68B 63.63B 8.03B 8.23B 1.41
Drug Manufacturers - General icon
LLY
Lilly Eli Co
865.00 822.10B 45.04B 10.59B -2.28B 11.71
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
83.74 371.73B 42.09B 14.65B 10.11B 3.2833
Drug Manufacturers - General icon
JNJ
Johnson Johnson
156.13 344.63B 88.82B 14.07B 19.03B 5.79
Drug Manufacturers - General icon
ABBV
Abbvie Inc
191.83 338.99B 56.33B 4.28B 15.62B 2.40
Drug Manufacturers - General icon
MRK
Merck Co Inc
86.54 251.88B 64.17B 17.12B 14.84B 6.7297

Pfizer Inc Stock (PFE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-10 Fortgesetzt BofA Securities Neutral
2024-11-15 Eingeleitet Wolfe Research Underperform
2024-10-25 Fortgesetzt Citigroup Neutral
2024-10-17 Eingeleitet Bernstein Mkt Perform
2024-08-07 Hochstufung Daiwa Securities Neutral → Outperform
2024-03-22 Herabstufung Argus Buy → Hold
2024-02-23 Eingeleitet Guggenheim Buy
2024-01-04 Herabstufung TD Cowen Outperform → Market Perform
2023-10-20 Fortgesetzt UBS Neutral
2023-10-16 Hochstufung Jefferies Hold → Buy
2023-07-17 Bestätigt JP Morgan Neutral
2023-07-14 Eingeleitet HSBC Securities Buy
2023-06-29 Herabstufung Credit Suisse Outperform → Neutral
2023-05-11 Herabstufung Daiwa Securities Outperform → Neutral
2023-03-06 Eingeleitet Jefferies Hold
2023-02-07 Hochstufung Daiwa Securities Neutral → Outperform
2023-01-26 Herabstufung UBS Buy → Neutral
2023-01-17 Herabstufung Wells Fargo Overweight → Equal Weight
2023-01-04 Herabstufung BofA Securities Buy → Neutral
2022-12-13 Hochstufung Goldman Neutral → Buy
2022-11-18 Eingeleitet Credit Suisse Outperform
2022-05-23 Eingeleitet SVB Leerink Mkt Perform
2022-04-06 Fortgesetzt Morgan Stanley Equal-Weight
2022-01-05 Hochstufung BofA Securities Neutral → Buy
2022-01-03 Bestätigt Bernstein Mkt Perform
2021-12-20 Bestätigt Cowen Outperform
2021-12-17 Eingeleitet Goldman Neutral
2021-12-13 Hochstufung UBS Neutral → Buy
2021-12-09 Eingeleitet Wells Fargo Overweight
2021-11-19 Eingeleitet BMO Capital Markets Outperform
2021-07-27 Fortgesetzt Truist Buy
2021-05-06 Herabstufung Mizuho Buy → Neutral
2021-04-07 Fortgesetzt RBC Capital Mkts Sector Perform
2021-02-04 Hochstufung DZ Bank Hold → Buy
2020-12-16 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2020-11-19 Fortgesetzt Goldman Neutral
2020-11-10 Fortgesetzt Bernstein Mkt Perform
2020-10-12 Herabstufung Atlantic Equities Overweight → Neutral
2020-09-29 Eingeleitet Berenberg Hold
2020-06-16 Eingeleitet SVB Leerink Mkt Perform
2020-02-27 Eingeleitet Barclays Equal Weight
2020-02-27 Hochstufung Standpoint Research Hold → Buy
2020-02-06 Eingeleitet Mizuho Buy
2020-01-07 Eingeleitet RBC Capital Mkts Outperform
2019-10-17 Fortgesetzt BofA/Merrill Neutral
2019-07-30 Herabstufung BofA/Merrill Buy → Neutral
2019-07-30 Herabstufung Morgan Stanley Overweight → Equal-Weight
2019-06-04 Fortgesetzt Morgan Stanley Overweight
2019-02-20 Fortgesetzt Citigroup Neutral
2019-01-31 Hochstufung Argus Hold → Buy
2019-01-31 Hochstufung Credit Suisse Neutral → Outperform
2019-01-23 Herabstufung UBS Buy → Neutral
2018-12-11 Herabstufung JP Morgan Overweight → Neutral
2018-11-01 Herabstufung BMO Capital Markets Outperform → Market Perform
Alle ansehen

Pfizer Inc Aktie (PFE) Neueste Nachrichten

pulisher
08:07 AM

Kentucky Trust Co Buys New Stake in Pfizer Inc. (NYSE:PFE) - MarketBeat

08:07 AM
pulisher
07:08 AM

Pfizer Inc. (NYSE:PFE) Shares Sold by Capital Advisors Inc. OK - MarketBeat

07:08 AM
pulisher
06:57 AM

Certuity LLC Grows Stock Holdings in Pfizer Inc. (NYSE:PFE) - MarketBeat

06:57 AM
pulisher
06:57 AM

Community Financial Services Group LLC Sells 11,699 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat

06:57 AM
pulisher
06:40 AM

Louisiana State Employees Retirement System Cuts Stock Position in Pfizer Inc. (NYSE:PFE) - MarketBeat

06:40 AM
pulisher
06:40 AM

Pfizer Inc. (NYSE:PFE) Shares Sold by Beacon Financial Group - MarketBeat

06:40 AM
pulisher
06:16 AM

Harbor Advisory Corp MA Sells 24,417 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat

06:16 AM
pulisher
06:11 AM

17,720 Shares in Pfizer Inc. (NYSE:PFE) Bought by Augustine Asset Management Inc. - MarketBeat

06:11 AM
pulisher
06:04 AM

Pfizer: 3 Key Risks That Warrant A Sell (NYSE:PFE) - Seeking Alpha

06:04 AM
pulisher
05:34 AM

Pediatric Vaccine Market Research Report 2025: Merck & Co. - GlobeNewswire

05:34 AM
pulisher
05:25 AM

Sovran Advisors LLC Takes Position in Pfizer Inc. (NYSE:PFE) - MarketBeat

05:25 AM
pulisher
03:11 AM

Uncover the Next Big Investment Opportunity: Why Pfizer Is a Top Pick - Jomfruland.net

03:11 AM
pulisher
02:13 AM

Alloy Therapeutics Establishes Multi-Year Collaboration with Pfizer to Develop New Antibody Discovery Platform - BioSpace

02:13 AM
pulisher
12:00 PM

Pfizer, Alloy Therapeutics unite on new antibody discovery platform - Medical Dialogues

12:00 PM
pulisher
Feb 11, 2025

Brokers Issue Forecasts for Pfizer's Q3 Earnings (NYSE:PFE) - MarketBeat

Feb 11, 2025
pulisher
Feb 11, 2025

Pfizer Seeks FDA Clearance For COVID-19 Vaccine In Younger Children - BW Healthcare World

Feb 11, 2025
pulisher
Feb 11, 2025

Alloy Partners with Pfizer to Develop New Antibody Discovery Platform - Contract Pharma

Feb 11, 2025
pulisher
Feb 11, 2025

Pfizer's Options Frenzy: What You Need to Know - Benzinga

Feb 11, 2025
pulisher
Feb 11, 2025

Pfizer (NYSE:PFE) Stock Price Down 1.1%Here's What Happened - MarketBeat

Feb 11, 2025
pulisher
Feb 11, 2025

Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo - Benzinga

Feb 11, 2025
pulisher
Feb 11, 2025

Alloy and Pfizer in latest strategic collaboration - The Pharma Letter

Feb 11, 2025
pulisher
Feb 11, 2025

Pfizer's investigational candidate combo cuts prostate cancer progression by 49% in phase 1 - Fierce Biotech

Feb 11, 2025
pulisher
Feb 11, 2025

Pfizer: strategic collaboration with Alloy extended -February 11, 2025 at 10:56 am EST - Marketscreener.com

Feb 11, 2025
pulisher
Feb 11, 2025

Jefferies raises Pfizer stock price target to $34, maintains Buy - Investing.com

Feb 11, 2025
pulisher
Feb 11, 2025

Leaked Conference Article Shows Pfizer’s Positive Phase I Prostate Cancer Data - BioSpace

Feb 11, 2025
pulisher
Feb 11, 2025

Jefferies Adjusts Price Target on Pfizer to $34 From $33 -February 11, 2025 at 09:55 am EST - Marketscreener.com

Feb 11, 2025
pulisher
Feb 11, 2025

Why Pfizer Stock Popped Today - AOL

Feb 11, 2025
pulisher
Feb 11, 2025

Pfizer reports positive long-term results for Padcev, Keytruda combo in urothelial cancer - World Pharmaceutical Frontiers

Feb 11, 2025
pulisher
Feb 11, 2025

Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Nasdaq

Feb 11, 2025
pulisher
Feb 11, 2025

Active Pharmaceutical Ingredients (API) Market Growth, Trends, Demand & Outlook 2025-2032 | Teva - EIN News

Feb 11, 2025
pulisher
Feb 11, 2025

Pfizer Inc. (NYSE:PFE) Shares Sold by First Fiduciary Investment Counsel Inc. - MarketBeat

Feb 11, 2025
pulisher
Feb 11, 2025

Pfizer Inc. (NYSE:PFE) Position Increased by Essex Financial Services Inc. - MarketBeat

Feb 11, 2025
pulisher
Feb 11, 2025

Sapient Capital LLC Has $13.79 Million Stock Position in Pfizer Inc. (NYSE:PFE) - MarketBeat

Feb 11, 2025
pulisher
Feb 11, 2025

Pfizer Inc. (NYSE:PFE) Shares Sold by Savant Capital LLC - MarketBeat

Feb 11, 2025
pulisher
Feb 11, 2025

Chronic Pain Market Detailed In New Research Report 2025 | Pfizer - openPR

Feb 11, 2025
pulisher
Feb 11, 2025

Strategic Financial Concepts LLC Buys Shares of 85,974 Pfizer Inc. (NYSE:PFE) - MarketBeat

Feb 11, 2025
pulisher
Feb 11, 2025

Pfizer To Sell All Its Drugs At Non-profit Price In Low-income Countries - BW Healthcare World

Feb 11, 2025
pulisher
Feb 11, 2025

Sangamo Therapeutics: Challenging Road Ahead After Pfizer Exit (NASDAQ:SGMO) - Seeking Alpha

Feb 11, 2025
pulisher
Feb 10, 2025

Leo Wealth LLC Has $949,000 Stock Holdings in Pfizer Inc. (NYSE:PFE) - MarketBeat

Feb 10, 2025
pulisher
Feb 10, 2025

Pfizer Inc. (NYSE:PFE) Shares Sold by Slocum Gordon & Co LLP - MarketBeat

Feb 10, 2025
pulisher
Feb 10, 2025

Cantor Fitzgerald Investment Advisors L.P. Trims Stock Position in Pfizer Inc. (NYSE:PFE) - MarketBeat

Feb 10, 2025
pulisher
Feb 10, 2025

Wilmington Savings Fund Society FSB Has $8.27 Million Position in Pfizer Inc. (NYSE:PFE) - MarketBeat

Feb 10, 2025
pulisher
Feb 10, 2025

Archer Investment Corp Sells 33,232 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat

Feb 10, 2025
pulisher
Feb 10, 2025

Golden State Wealth Management LLC Makes New Investment in Pfizer Inc. (NYSE:PFE) - MarketBeat

Feb 10, 2025
pulisher
Feb 10, 2025

BLB&B Advisors LLC Lowers Position in Pfizer Inc. (NYSE:PFE) - MarketBeat

Feb 10, 2025
pulisher
Feb 10, 2025

Pfizer Inc. (NYSE:PFE) Shares Sold by Bleakley Financial Group LLC - MarketBeat

Feb 10, 2025
pulisher
Feb 10, 2025

Pfizer Inc. (NYSE:PFE) Shares Purchased by Quattro Financial Advisors LLC - MarketBeat

Feb 10, 2025
pulisher
Feb 10, 2025

Pfizer (NYSE:PFE) Shares Down 0.8%Time to Sell? - MarketBeat

Feb 10, 2025
pulisher
Feb 10, 2025

Pfizer and Astellas report improved survival in bladder cancer trial - Investing.com India

Feb 10, 2025
pulisher
Feb 10, 2025

Pfizer, Astellas Cite 'Durable Benefit' in More Trial Results of Padcev Plus Keytruda in Urothelial Cancer - Marketscreener.com

Feb 10, 2025
pulisher
Feb 10, 2025

Pfizer And Astellas' Padcev Plus Keytruda Shows Long-Term Efficacy In First-Line Treatment Of Locally Advanced Or Metastatic Urothelial Cancer - Marketscreener.com

Feb 10, 2025

Finanzdaten der Pfizer Inc-Aktie (PFE)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
drug_manufacturers_general SNY
$53.90
price up icon 1.16%
$296.66
price up icon 0.63%
$96.14
price up icon 0.69%
drug_manufacturers_general NVS
$107.75
price up icon 0.84%
drug_manufacturers_general MRK
$86.54
price up icon 0.16%
Kapitalisierung:     |  Volumen (24h):